



Alternative Testverfahren und intelligente Teststrategien

– Position der EU-Kommission –

Thomas Hartung & ECVAM Team

*Institute for Health and Consumer Protection (IHCP)
Ispra (Va), Italy*

<http://ecvam.jrc.it>



Purposes of animal experiments in 2002

Total number	10,700,000	100%
Safety evaluations	1,060,000	10 %
Agricultural chemicals	123, 000	1 %
Industrial chemicals	136,000	1 %
Cosmetics	2,700	0.025%

REACH

30,000 chemicals > 1 t per year to be assessed

Various Estimates:

- ⇒ **Costs:** 2,4 (ECB) – 8 (MRC) billion €
- ⇒ **Animal numbers:** 3,9 (ECB) – 43 (BfR) million
- ⇒ **Time foreseen:** 11 (ECB) – 40 (MRC) years

Calculated savings up to 70% of costs and animal numbers, if intelligent testing strategies are applied (i.e. read-across, QSAR, in vitro, refined in vivo).



**billions of Euro, millions of animals,
decades of testing**



The ECVAM Strategy

- Analyse the animal test >>> **REFINE, BENCHMARKS**
- Analyse the prevalence of health effects >>> **TEST STRATEGIES**
- Analyse what is available >>> **INVENTORY**
- Coach development of tests needed >>> **INTEGRATED PROJECTS**
- Optimise validation process >>> **MODULAR APPROACH**
- Ensure Quality >>> **GLP /GCCP**
- Plan strategies >>> **400 EXPERTS**
- Bundle all stakeholders >>> **INTERNATIONAL COLLABORATION**



The ECVAM Strategy

- Analyse the animal test >>> **REFINE, BENCHMARKS**
- Analyse the prevalence of health effects >>> **TEST STRATEGIES**
- Analyse what is available >>> **INVENTORY**
- Coach development of tests needed >>> **INTEGRATED PROJECTS**
- Optimise validation process >>> **MODULAR APPROACH**
- Ensure Quality >>> **GLP /GCCP**
- Plan strategies >>> **400 EXPERTS**
- Bundle all stakeholders >>> **INTERNATIONAL COLLABORATION**

Ecotoxicology

Reduction alternative – Threshold (step-down) approach




- 2003: 1.6 Mio fish used - increase of 970,000
- REACH: estimates up to 4 Mio
- Retrospective analysis of ecotoxicological data of chemicals and plant protection products (ECVAM & ECB)
- Possible reduction of 55-70% in number of fish used
- Peer review 2005

Skin Irritation

NCD-Prevalence (n = 1238)

EUS 1500	No label: 93.8% (1161)	R 38: 6.2% (77)	
GHS	NI: 91.8%	MI: 6.0%	I: 2.2%



Skin Irritation Validation Study

EPISKIN	EPIDERM	SIFT
L'Oréal (F)	ZEBET (D)	Syngenta (UK)
Unilever (UK)	Institute for In Vitro Sciences (USA)	DuPont (USA)
Sanofi-Synthélabo (F)	BASF (D)	TNO (NL)

The ECVAM Strategy

- Analyse the animal test >>> REFINE, BENCHMARKS
- Analyse the prevalence of health effects >>> **TEST STRATEGIES**
- Analyse what is available >>> INVENTORY
- Coach development of tests needed >>> INTEGRATED PROJECTS
- Optimise validation process >>> MODULAR APPROACH
- Ensure Quality >>> GLP /GCCP
- Plan strategies >>> 400 EXPERTS
- Bundle all stakeholders >>> INTERNATIONAL COLLABORATION



EYE IRRITATION in vivo


- **5 – 15%** underprediction as **inter-animal variance** within a single test
- **< within-laboratory variance** (day-to-day variances, performers)
- **< between-laboratory variance** (laboratory set-up, animal strains, performance)
- **< predictive capacity for human health effect**

No comprehensive analysis of high-quality data exists;

Review in preparation

→ our tools are not perfect

The prevalence concept



- **Negative predictive value R41:**
85% accuracy: 97%
- **Positive predictive value R41:**
85% accuracy: 51%

→ **Every test (in vivo or in vitro) will have many false-positives and few false-negatives**


→ **Identify the negatives**



The ECVAM Strategy

- Analyse the animal test >>> REFINE, BENCHMARKS
- Analyse the prevalence of health effects >>> TEST STRATEGIES
- **Analyse what is available >>> INVENTORY**
- Coach development of tests needed >>> INTEGRATED PROJECTS
- Optimise validation process >>> MODULAR APPROACH
- Ensure Quality >>> GLP /GCCP
- Plan strategies >>> 400 EXPERTS
- Bundle all stakeholders >>> INTERNATIONAL COLLABORATION

Vision 7th Amendment of Cosmetics Directive



Taskforce chaired by ECVAM:

- 5 DG of Commission
- 5 Trade associations
- 3 Animal welfare NGOs
- OECD

75 experts >>> 330 page report

↑
Stop finished products
& ECVAM-validated alternatives

↑
Deadlines ingredients




ECVAM DATABASE SERVICE ON ALTERNATIVE METHODS TO ANIMAL EXPERIMENTATION

Registration Tendency 2001-2005

4325 registered users from 65 countries

May '05



Data content

In addition to the existing information content, 2 new sectors:

- *In vitro* Neurotoxicity
- *In vitro* Metabolism-mediated Toxicity




The ECVAM Strategy

- Analyse the animal test >>> REFINE, BENCHMARKS
- Analyse the prevalence of health effects >>> TEST STRATEGIES
- Analyse what is available >>> INVENTORY
- **Coach development of tests needed >>> INTEGRATED PROJECTS**
- Optimise validation process >>> MODULAR APPROACH
- Ensure Quality >>> GLP /GCCP
- Plan strategies >>> 400 EXPERTS
- Bundle all stakeholders >>> INTERNATIONAL COLLABORATION

The new dimension of development of alternative methods



DG RTD



DG JRC
ECVAM



Policy-DGs
ECB (DG JRC)



Collaboration in 3 Integrated Projects

(about 90 partners & 30 million Euro)

“ReProTect”, “A-Cute-Tox” & “Sens-it-iv”



Acute toxicity (LD_{50} test)

37% of all animals in toxicology (2002)

- **Seventies** **150** animals per substance
- **Eighties** harmonised OECD:
45 animals
- **Nineties** tiered testing strategies:
15 animals
- **Ongoing** ECVAM / ICCVAM study:
5 animals (?)
- **Starting** **A-Cute-Tox: no animals (?)**



Acute Systemic Toxicity

A-Cute-Tox

Integrated Project

37 partners (14 states), granted 9 M€


17 universities, 10 SME, 2 industry, 6 institutes

Coordinator:

Expertradet, Sweden



New concept: Reversed high-throughput



Pharma:

1 million subst.

1 valid cell model


ECVAM:

300+ substances

**Variation of cell
models**



Reproductive Toxicology



Integrated Project

**26 partners (9 states), granted 9 M€
9 universities, 5 SME, 3 industry, 7 gov.**

Coordinators:

Univ. Tübingen / ECVAM



Sensitization (Skin & Lung)

Sens-it-iv

Integrated Project

31 participants (11 states), 10 Universities, 6 research institutes, 6 Industries, 7 SME, 1 foundation, JRC

Coordinators

Novozymes / MPI Freiburg



The ECVAM Strategy


- Analyse the animal test >>> REFINE, BENCHMARKS
- Analyse the prevalence of health effects >>> TEST STRATEGIES
- Analyse what is available >>> INVENTORY
- Coach development of tests needed >>> INTEGRATED PROJECTS
- **Optimise validation process >>> MODULAR APPROACH**
- Ensure Quality >>> GLP /GCCP
- Plan strategies >>> 400 EXPERTS
- Bundle all stakeholders >>> INTERNATIONAL COLLABORATION

Challenges to the validation process

- **Efficiency of the process** → **reduced testing**
- **Use of existing data** → **weight-of evidence
retrospective valid.**
- **New technologies
(toxicogenomics,
transgenics, (Q)SAR)** → **adaption of
principles**
- **Amendments of validated
tests** → **incremental
validation**


Modular Approach to Validation

Hartung, et. al. ATLA 32, 467-472, 2004




Mutagenicity/Genotoxicity

2nd largest testing requirement



Micronucleus Test *in vitro*




- 1st retrospective validation
- Peer review foreseen summer '05
- Parallel OECD activity

ECB/ECVAM work on (Q)SARs

- **External contracts**
Acute fish toxicity, Skin penetration, Skin sensitisation, Nuclear hormone receptor binding
- 2. **Collaborative studies**
Skin sensitisation, Acute local toxicity

Contribution to OECD activities

- Principles of (Q)SAR validation
- 2. (Q)SAR terminology document
- 3. Guidance Document on (Q)SAR validation
- 4. Guidance on Chemical Categories





The ECVAM Strategy

- Analyse the animal test >>> REFINE, BENCHMARKS
- Analyse the prevalence of health effects >>> TEST STRATEGIES
- Analyse what is available >>> INVENTORY
- Coach development of tests needed >>> INTEGRATED PROJECTS
- Optimise validation process >>> MODULAR APPROACH
- **Ensure Quality >>> GLP /GCCP**
- Plan strategies >>> 400 EXPERTS
- Bundle all stakeholders >>> INTERNATIONAL COLLABORATION

GLP and GCCP

Joint Research Centre

OECD Advisory Document No 14 "The Application of the GLP Principles to in vitro studies" (ENV/JM/MONO(2004)26)




GLP

ECVAM Workshop Report
OLIVE (ECVAM laboratories)

OECD Draft Consensus Document

OECD Advisory Document No 14



1999

2000

2001

2002

2003

2004

2005

GCCP


World Conference Workshop

ECVAM Task Force Report

ECVAM draft Guidance Document

ECVAM final Guidance Document

Coecke et al (2005)
Guidance on Good Cell Culture Practice;
ATLA, July issue





The ECVAM Strategy

- Analyse the animal test >>> REFINE, BENCHMARKS
- Analyse the prevalence of health effects >>> TEST STRATEGIES
- Analyse what is available >>> INVENTORY
- Coach development of tests needed >>> INTEGRATED PROJECTS
- Optimise validation process >>> MODULAR APPROACH
- Ensure Quality >>> GLP /GCCP
- **Plan strategies >>> 400 EXPERTS**
- Bundle all stakeholders >>> INTERNATIONAL COLLABORATION



Components of Intelligent Testing Strategies

- (i) *In-vitro* tests**
- (ii) Optimised *in-vivo* tests**
- (iii) Thresholds of toxicological concern**
- (iv) In silico (SARs, QSARs, modelling)**
- (v) Read-across and chemical categories**
- (vi) Exposure assessment/exposure-based waiving**


Eye Irritation

Evaluation of 10 methods (with ICCVAM)

Organotypic methods

Reconstituted human tissue models


Cell cytotoxicity- / function- based methods



Identification of Testing Strategies

Eye Irritation Expert Meeting, Feb 05

Evaluation of collected data



R36: Irritating to eyes; R41: Severe eye irritant



Review of the in vivo Draize Eye Test

Based on literature

Evaluation of existing data

Other activities: *Validation of LVET (refined in vivo)*
Ocular Toxicity Mechanistic Symposia, May 05
(with ICCVAM)


Eye Irritation Expert Meeting

Feb. 8-11, 2005

Joint Research Centre

Range of Irritation

Nominated Test Methods



Physico-chemical class/formulations



The ECVAM Strategy

- Analyse the animal test >>> REFINE, BENCHMARKS
- Analyse the prevalence of health effects >>> TEST STRATEGIES
- Analyse what is available >>> INVENTORY
- Coach development of tests needed >>> INTEGRATED PROJECTS
- Optimise validation process >>> MODULAR APPROACH
- Ensure Quality >>> GLP /GCCP
- Plan strategies >>> 400 EXPERTS
- **Bundle all stakeholders >>> INTERNATIONAL COLLABORATION**

ECVAM Collaboration Striving for International Harmonization

ICCVAM

- **Joint workshops and studies**
- **Validation of toxicogenomics**
- **GLP**
- **Mutual observer status**
- **Harmonisation of peer-review process**
- **Consultation group between ESAC and ICCVAM**
- **Joint submissions to OECD**
- **Personnel exchange**

OECD

- **Secondments**
- **Observer status on ESAC**
- **Document 34 on validation**
- **GLP in vitro guidance document**
- **Collaboration in validations**
 - **endocrine disrupters**
 - **micronucleus test**
 - **cell transformation assay**




Carcinogenicity

The only regulatory accepted test:
2 years animal test (1 M€chemical)



Alternative: *in vitro* Cell Transformation Assay



Prevalidation initiated in 11/2004

1st study involving EU, USA, Japan



***Nothing is as strong as an idea
whose time has come.***

Victor Hugo